Background Pakistan and Afghanistan are two of the three remaining countries yet to interrupt wild-type poliovirus transmission. The increasing incidence of poliomyelitis in these countries during 2010-11 led the Executive Board of WHO in January, 2012, to declare polio eradication a "programmatic emergency for global public health". We aimed to establish why incidence is rising in these countries despite programme innovations including the introduction of new vaccines.
Introduction
The sustained eff ort of the Global Polio Eradication Initiative (GPEI) to vaccinate children in Afghanistan and Pakistan reduced cases of serotype 1 and 3 polio myelitis between 2005 and 2007 in both countries. 1 However, since 2008, the annual incidence of polio myelitis in Afghanistan and Pakistan has increased, and in 2011, Pakistan reported the highest incidence of polio myelitis in a decade. 2 Over 60% of all cases in endemic countries and 34% of cases worldwide were recorded in Pakistan, 2 which risks being the last country to interrupt transmission, and so is jeopardising global polio erad ication. In July, 2011, cases of poliomyelitis identifi ed in children in the western region of China (Xinjiang autonomous region) were genetically linked to cases in Pakistan, showing the risk to other countries of poliomyelitis in Pakistan. 3 Since the turn of the century there have been several developments in the GPEI strategy. Until 2005, GPEI relied on the trivalent form of the oral poliovirus vaccine (OPV), which contains all three serotypes. Use of trivalent OPV results in reduced eff ectiveness against individual serotypes, in particular serotypes 1 and 3, because of interference between Sabin vaccine strains. 4 To address this problem, serotype 1 and 3 monovalent OPVs were produced and licensed in 2005 (wild-type poliovirus serotype 2 was eliminated in 1999). These vaccines are more immunogenic and more eff ective than the trivalent vaccine. [5] [6] [7] In late 2009 and early 2010, a serotype 1 and 3 bivalent OPV was licensed and pre-qualifi ed by WHO and introduced into Afghanistan and Pakistan after its immunogenicity was shown to be non-inferior compared with monovalent OPV for each serotype in a study among neonates in India. 8 Since the introduction of these improved vaccines to Pakistan and Afghanistan, 9 one would have expected a reduction in cases. However, polio eradication in Pakistan has been aff ected by weak service delivery 10 and was identifi ed by the GPEI Independent Monitoring Board in 2010 as a country that was not on track for elimination of poliomyelitis. 2, 11 The eradication of poliomyelitis in parts of Pakistan and Afghanistan has been complicated by armed confl ict, security concerns (eg, areas being inaccessible to vaccination teams because of security concerns, and the movement of families to escape potential confl ict), cultural barriers, and natural disasters that have limited accessibility of vaccination teams to target populations. Because of the deterioration of the programme in Pakistan and Afghanistan in 2011, and ongoing transmission of polioviruses in Nigeria, on Jan 21, 2012, the WHO Executive Board declared polio eradication a "program matic emergency for global public health". 12 Because poliovirus remains endemic in Pakistan and Afghanistan, identifying where the programme is failing to immunise children is imperative, so that appropriate improvements to the vaccination programme can be made. Although independent monitoring of immunisation campaigns can provide an esti mate of coverage, 10 these data do not easily translate to estimates of serotype-specifi c immunity. Further more, recent lot quality assurance sampling of vaccination coverage during campaigns suggested that independent monitoring might signifi cantly over estimate coverage. 13 Recording a child's vaccination history during the investigation of acute fl accid paralysis provides an opportunity to assess vaccination coverage and eff ectiveness in Pakistan and Afghanistan. We used vaccination history data from children with acute fl accid paralysis to estimate the clinical eff ectiveness and population immunity induced by OPVs. We assessed programme performance over time in diff erent regions and examined the association between estimated serotype-specifi c population immunity and the incidence of poliomyelitis.
The results are discussed to highlight improvements that must be made to ensure elimination of poliomyelitis in these endemic countries.
Methods

Data collection
Children are vaccinated using the OPV through either routine immunisation as part of the WHO Expanded Programme on Immunisation or via supplementary immunisation activities, where vaccination teams aim to vaccinate all children aged 0-4 years within a few days through fi xed booths and mobile vaccination teams. Initial case investigation includes an interview with the child's caregiver to record demographic information (age, date of birth, sex, district of residence, and details of illness) and vaccination history, including the num ber of OPV doses received through routine and supplementary immunisation activities. Two stool samples are collected at least 24 h apart within 14 days of the onset of paralysis and are sent under appropriate conditions to the WHO reference laboratory in Islamabad, Pakistan, where they are tested for the presence of wild-type and vaccine-related poliovirus. 14 We analysed data from 46 977 children in Pakistan and Afghanistan who had an onset of acute fl accid paralysis between Jan 1, 2001, and Dec 31, 2011. Although acute fl accid paralysis surveillance began in Pakistan in 1995 and in Afghanistan in 1997, a virological case defi nition based on isolation of wild-type poliovirus from stool samples was not adopted until January, 2000, in Pakistan and January, 2001, in Afghanistan. 15, 16 Further more, indicators of surveillance performance in both countries before 2001, were poor and did not meet international standards (appendix). 15 We therefore excluded children with acute fl accid paralysis reported before January, 2001.
Children with acute fl accid paralysis and wild-type poliovirus detected in at least one stool sample were defi ned as poliomyelitis cases. Children with acute fl accid paralysis and two adequate stool samples in which neither wild-type nor vaccine-related poliovirus were isolated were defi ned as non-polio acute fl accid paralysis. Children without suffi cient information about age, date of birth, district of residence, or OPV vaccine history, and children without two adequately collected stool samples and with residual paralysis compatible with poliomyelitis (compatible cases), were excluded from the analysis (appendix). We also excluded children with vaccine-derived poliovirus isolated from their stool. Serotype 2 circulating vaccine-derived poliovirus was isolated from six children in Afghanistan between June, 2010, and January 2011; no other circulating vaccine-derived polio virus was reported from Afghanistan or Pakistan. 17 For each acute fl accid paralysis case, the numbers of OPV doses received through routine and supplementary immunisation activities, as reported by the caregiver, were separately recorded. All OPV doses received through routine services were trivalent. Vaccinations Inconsistencies between the reported number of OPV doses and the supplementary immun isation activity schedule can occur if not all children less than 5 years old in a district were immunised during a supplementary immunisation activity, if additional OPV doses were received outside of the district of residence, or if there is caregiver recall error. Institutional ethics approval was not sought because this is a retrospective study and the databases are anonymised and free of personally identifi able information.
Statistical analysis
Summary statistics were reported separately for each country and region. Afghanistan and Pakistan were divided into seven regions defi ned by the GPEI according to patterns of poliovirus epidemiology. Pakistan was separated into Balochistan province; Khyber Pakhtunkhwa (KP) province; the Federally Administered Tribal Areas (FATA); a grouping of Punjab province, Gilgit-Baltistan, Azad Jammu Kashmir, and Islamabad Capital Territory (grouped as Punjab+); and Sindh province. Afghanistan was grouped into the southern provinces of Hilmand, Kandahar, Nimroz, Uruzgan, and Zabul, and the rest of Afghanistan as the remaining region. Incidence rates by region were calculated using the population sizes from the most recent census data from the Afghanistan Information Management Services and the Population Census Organisation, Pakistan. A smoothing cubic spline with 90 degrees of freedom was fi tted to the weekly incidence of poliomyelitis and the non-polio acute fl accid paralysis rate.
We used a conditional logistic regression model to estimate the odds of paralysis by poliovirus serotypes 1 and 3 as a function of the number of doses of each vaccine received before the onset of paralysis. 19 The log odds of paralysis was given by: and, x t are the number of monovalent, bivalent, and trivalent OPV doses received. The amount of exposure to wild virus, ε, for each matched pair is unknown, but was eliminated from the analysis by maximising the conditional likelihood. 20 Cases of poliomyelitis were matched 1:1 with randomly chosen control children with non-polio acute fl accid paralysis by the methods described previously (eligible control children were randomly selected for each case without replacement, taking the cases in a random sequence; appendix). Cases and control children were matched by age and the date of onset of paralysis (within 3 months) and by district for Pakistan and province for Afghanistan (provinces in Afghanistan are similar in population size to districts in Pakistan).
To calculate vaccine-induced population immunity, children with non-polio acute fl accid paralysis (control children) were assumed to represent a random sample of children in the population of the corresponding age. The probability of a child being directly protected by vaccin ation against serotype 1 poliomyelitis was calculated from the estimated number of monovalent, bivalent, and trivalent OPV doses received and the estimated eff ectiveness of these vaccines as:
Vaccine-induced population immunity among children aged 0-2 years was estimated from the average of this quantity calculated for each single year age group in the acute fl accid paralysis database, weighted to represent the underlying age distribution of the population.
We report vaccine coverage on the basis of the proportion of children aged 0-2 years with non-polio acute fl accid paralysis who were reported to have received more than three doses of OPV. Uncertainty in vaccine coverage was accounted for by taking 10 000 bootstrap samples (with replacement) from the non-polio acute fl accid paralysis cases and recording the percentage of children who received four or more doses for each sample. 21 We report the 2·5th and 97·5th percentiles for these bootstrap samples. We used a linear model to estimate the slope of temporal trends in annual vaccine coverage for each region from 2006 to 2011, and to report the strength of the decrease in coverage a p value was used, where p<0·05 denotes that at least 95% of bootstrapped samples had a decrease in coverage. Linear trends in vaccine-induced population immunity against serotype 1 were assessed in the same way, but uncertainty in vaccine eff ectiveness was also included in bootstrap replicates by randomly sampling from a multivariate log-normal distribution with means and variancecovariance matrix given by the conditional logistic regression used to estimate vaccine eff ectiveness. Estimated population immunity and annual incidence of poliomyelitis were compared for each district-year separately. The correlation between population immunity and incidence was tested by Spearman's rank correlation coeffi cient. The coverage of routine immun isation was assessed on the basis of the proportion of children with non-polio acute fl accid paralysis who were reported to have received at least three doses of trivalent OPV through routine services.
Role of the funding source
The funders of the study had no role in the study design, data collection, data analysis, data interpretation, decision to publish, or preparation of the manuscript. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between reported acute fl accid paralysis cases. This increase was followed by an increase in Afghanistan in 2011 (fi gure 1). The locations of poliomyelitis cases were spatially aggregated; the highest numbers of serotype 1 poliomyelitis cases were reported in Karachi, Swat, and Khyber districts in Pakistan (fi gure 2). In Afghanistan, Maywand and Shah Wali Kot districts within Kandahar province had the most cases during the study period. In 2011, there were over 20 cases in Killa Abdullah district in Balochistan and between 15 and 20 cases in Quetta and Pishin in Balochistan province and Khyber in FATA (fi gure 2). In 2011, two cases of poliomyelitis caused by serotype 3 were identifi ed, both in Khyber district in FATA, Pakistan.
Of the 883 serotype 1 poliomyelitis cases, 535 (61%) were matched with suitable controls (table). The esti mated clinical eff ectiveness of a dose of trivalent OPV against serotype 1 poliomyelitis was 12·5% (95% CI 5·6-18·8) compared with 23·4% (10·4-34·6) for bi va lent OPV (likelihood ratio test p=0·067) and 34·5% (16·1-48·9) for monovalent OPV (p=0·007). The esti mated eff ectiveness of bivalent OPV was non-inferior compared with monovalent OPV (p=0·21). There was no evidence of signifi cant variation in vaccine eff ectiveness by country or region within these countries or by number of vaccine doses previously received (likelihood ratio test p=0·22 for the per-dose trivalent model; appendix). There were not enough cases of serotype 3 poliomyelitis between 2001 and 2011 to allow accurate estimation of the eff ectiveness of each OPV against this serotype.
The estimated coverage with more than three OPV doses among children aged 0-2 years in Afghanistan and Pakistan was moderate to high (above 70%). However, in Balochistan, FATA, KP, and southern Afghanistan there was a signifi cant linear decrease in coverage from 2006, to 2011, (fi gure 3; appendix). Coverage estimates in Sindh, Punjab+, and the rest of Afghanistan remained stable from 2006 to 2011. In Balochistan and FATA, there was also a decrease during 2006-11 in the percentage of children aged 0-2 years who received three or more OPV doses through routine services (appendix). Routine immunisation coverage remained low in southern Afghanistan.
The percentage of children aged 0-2 years who were protected by direct vaccination against poliomyelitis varied by location and year (fi gure 3; appendix). Immunity to serotype 1 in FATA and Balochistan decreased, despite the use of more eff ective vaccines. Coverage estimates for Balochistan, KP, and all of Afghanistan further decreased in 2011 when compared with 2010, although vaccineinduced population immunity against serotype 1 either increased or remained stable, with the exception of southern Afghanistan.
We noted a signifi cant negative correlation (p<0·0001) between the ranked population immunity and annual incidence of serotype 1 poliomyelitis in each district (Pakistan) or province (Afghanistan; Spearman's ranked correlation coeffi cient -0·11; appendix).
Discussion
This study provides the fi rst estimates of the clinical eff ectiveness and population immunity induced by OPVs in Pakistan and Afghanistan, including the eff ectiveness of the bivalent vaccine (panel). Our fi ndings support the results from India, 8 which showed that the immunogenicity of two doses of bivalent OPV given to newborn babies was non-inferior compared with serotype 1 or 3 monovalent OPVs. Our results also compare favourably with the clinical protective eff ectiveness of the mono valent OPV in India (30%, 95% CI 19-41), 18 which was valuable in improving population immunity and led to the successful interruption of wild-type poliovirus trans mission in 2011. Consequently, bivalent OPV will be useful in boosting population immunity against both circulating serotypes during supplementary immun isation activities. Bivalent OPV will be used in six of the eight supplementary immunisation activities planned for 2012 in Pakistan and will be complemented with trivalent vaccine in the remaining two supplementary immun isation activities to maintain immunity to serotype 2.
The estimated eff ectiveness of trivalent OPV against serotype 1 poliomyelitis in Afghanistan and Pakistan was similar to that reported in India. 7, 19 The poor eff ectiveness of OPV in these settings might be partly explained by the high prevalence of diarrhoeal disease and enteric infections including enteroviruses that might interfere with seroconversion. 4, 22 In KP and FATA, the annual average incidence of enteroviruses in non-polio acute fl accid paralysis stool samples was about 30%, which is similar to that reported in Uttar Pradesh and Bihar in India (Grassly NC, unpublished) . Although this fi nding does not implicate enteroviruses specifi cally, it is consis tent with the potential role of enteric pathogens in the compromised eff ectiveness of OPV.
Since 2006, there has been a decrease in estimated vaccination coverage and population immunity against poliomyelitis in specifi c regions of Pakistan and Afghanistan, which correlated with an increased incidence of cases. In response to this epidemiological situation, the President of Pakistan launched a National Emergency Action Plan in early 2011. 9 Part of this action plan included a focus on 33 districts with a high incidence of poliomyelitis, largely in KP, FATA, Balochistan, and Sindh. 10 In late 2011, the National Emergency Action Plan was further augmented with tighter oversight and vigorous monitoring to improve quality in vaccination campaigns. 2 However, the analysis presented here suggests that vaccination coverage continued to decrease in 2011, especially in Balochistan. Additionally, coverage continues to be compromised by the ongoing confl ict in southern Afghanistan.
Immunisation is not the only intervention with inequitable access in Pakistan and Afghanistan, but poor access to it contributes with other social determinants to poor child health in these areas. 23 Armed confl ict and concerns about security are major challenges that can limit access to children during vaccination campaigns, in addition to disrupting routine health and immunisation services. 24 For example, we noted that access to routine immunisation decreased in Balochistan and FATA in Pakistan, with just 25-33% of children under 3 years old reported to have received three or more doses of OPV through routine services in 2011 (appendix). This fi nding contrasts with improvements in routine immunisation coverage in areas free from confl ict such as northern Afghanistan. However, weak service delivery has also resulted from poor management and scarcity of local accountability; 10, 25 even so, polio has been successfully eliminated during times of confl ict in many other countries. 24 The precision of our estimates of vaccine eff ectiveness might be limited by the accuracy of the caregiver's report of the number of doses of OPV received by a child and diffi culties in correctly inferring the type of vaccine received during supplementary immunisation activities. Although vaccination cards were used when recording the number of doses of trivalent OPV received through routine immunisation services, these cards were only available for 25% of children and the number of vaccine doses received through supplementary immunisation activities was not recorded. Errors in the reported numbers of vaccine doses among cases and controls could lead to an underestimate of vaccine eff ectiveness. Additionally, the inability of the statistical method of matching by location, time, and age to control for diff erences in exposure to wild-type polioviruses might further con tribute to underestimation of vaccine eff ectiveness.
We attempted to assess the extent of caregiver recall error in several ways, including by examining the correlation between caregiver reports of supplementary immunisation activity doses and administrative records of supplementary immunisation activities, the odds of poliomyelitis as a function of the reported number of doses of vaccine received, and the association between the estimated vaccine-induced population immunity on the basis of caregiver reports of vaccination history and the incidence of poliomyelitis. In each case, results based on caregiver recall were consistent with those expected based on the other data sources, although comparison with the supplementary immunisation activity schedule suggested that at higher dose numbers there was a preference for reporting seven, ten, 12, 15, and 20 doses (appendix). These fi ndings are in agreement with a study in India, 7 where information from detailed interviews with parents of children with poliomyelitis showed some small errors in recall of the number of vaccine doses received by their children but no consistent upwards or downwards bias. Furthermore, vaccination history is taken at a time when both the caregiver and interviewer are unaware of the polio status of the child, thus removing the possibility of diff erential reporting from cases and controls. The fi ndings of a greater eff ectiveness of monovalent OPVs and weak evidence of greater eff ectiveness of bivalent vaccine than trivalent OPV are therefore likely to be robust to recall error of caregivers. We also focused on children aged 0-2 years when estimating vaccination coverage and population immun ity to avoid recall errors that might have been more frequent among older children. Children in this age group were also chosen because they are more repre sentative of the at-risk population.
The negative correlation of population immunity with incidence shows protective immunity within the population. However, in some districts there was not the expected reduction in cases despite high estimated population immunity. A limitation of this analysis is that non-polio acute fl accid paralysis cases are assumed to be representative of the entire population. In reality, even within districts there are probably areas not reached by surveillance and vaccination teams, resulting in heterogeneities in population immunity that are not captured in the analysis.
In the past 10 years there have been many developments in the control of poliomyelitis that should enable elimination in Afghanistan and Pakistan. However, an increase in incidence has occurred despite the introduction of more effi cacious vaccines because of steep decreases in vaccination coverage. In 2011, 40% of children under 3 years old in Balochistan and FATA in Pakistan and in southern Afghanistan were estimated to be unprotected against serotype 1, the predominant circulating wild polio virus. If vaccination coverage during the two trivalent and four bivalent OPV campaigns planned in Afghanistan and Pakistan in 2012 could be
Panel: Research in context
Systematic review
We searched PubMed and Web of Science with the search terms "poliomyelitis AND (Pakistan OR Afghanistan)" and "bivalent AND poliovirus", with no date limits set, on March 7, 2012. For over 10 years the incidence and epidemiological status of poliomyelitis in both countries have been reported annually in the Weekly Epidemiological Record. 15 Monitoring of vaccine coverage during mass campaigns has been limited, but fi ndings from a lot-quality assurance sampling study in Pakistan suggested that coverage during mass campaigns in 2009 was low. 13 The only immunogenicity study of the present formulation of bivalent OPV that we identifi ed was done in India in 2008, in which the vaccine was non-inferior compared with monovalent vaccines for serotypes 1 and 3. 8 The eff ectiveness of this bivalent OPV has not been reported previously.
Interpretation
We found the eff ectiveness of serotypes 1 and 3 bivalent OPV against poliomyelitis caused by serotype 1 wild poliovirus to be non-inferior compared with monovalent OPV. However, despite the use of these more eff ective vaccines during recent vaccination campaigns, estimated population immunity among children in key regions of Afghanistan and Pakistan decreased between 2006 and 2011 as a result of substantial drops in vaccination coverage. This decrease in population immunity resulted in an increased incidence of serotype 1 poliomyelitis during 2010-11. Vaccination coverage must be considerably improved in 2012 through higher quality campaigns and routine programmes if global eradication of poliomyelitis is to be achieved.
increased to at least 80%, and if persistently missed children could be reached by the programme, the proportion of unprotected children would decrease to less than 10% and eradication would become feasible. To achieve this ambitious goal, major improvements in vaccination delivery will be needed in the face of armed confl ict and concerns about security.
